Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity.
This study was designed to develop a method for quantitative assessment of infarct size in the conscious animal based on serial changes of serum creatine phosphokinase (CPK) activity. From 11 experiments in which myocardial CPK was injected intravenously in conscious dogs, the average CPK distribution space and average CPK fractional disappearance rate from serum were found to be 11.4% of body weight and 0.48% min respectively. In other experiments, myocardial infarction was produced in 22 conscious dogs by constriction of a left coronary artery snare and serum CPK activity was determined at frequent intervals for 24 hr. Since myocardial CPK depletion reflects infarct size, infarct size was determined directly by analysis of myocardial CPK content in the same animals 24 hr after coronary artery occlusion. CPK released from the infarct was determined from observed changes in serum CPK activity analyzed according to a model taking into account the fraction of CPK released from an infarct and the rates of appearance and disappearance of CPK activity from serum. Infarct size was calculated on the basis of observed changes in serum CPK and compared to infarct size determined directly by analysis of myocardial CPK depletion. Agreement was close and results from all experiments fit the equation: [infarct size (g) determined from serum CPK] = 1.13 x [infarct size (g) determined from myocardial CPK] - 1.3, r = 0.96, n = 22. The method described is useful for accurate assessment of infarct size in the conscious animal and for detection of modification of infarct size produced by pharmacologic interventions.
D000818:Animals; D001783:Blood Flow Velocity; D002302:Cardiac Output; D003250:Constriction; D003331:Coronary Vessels / Q000601:surgery; D003402:Creatine Kinase / Q000032:analysis / Q000097:blood* / Q000378:metabolism; D004285:Dogs; D006321:Heart / Q000187:drug effects; D007545:Isoproterenol / Q000494:pharmacology; D009203:Myocardial Infarction / Q000201:enzymology* / Q000209:etiology / Q000473:pathology; D009206:Myocardium / Q000201:enzymology
D003402:Creatine Kinase; D007545:Isoproterenol